JS107 vs standard therapy for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, JS107, against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has continued to grow after at least one prior treatment. The cancer must have a specific protein called CLDN18.2 on its cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or gastroesophageal junction cancer that has gotten worse after at least one prior treatment including fluorouracil and platinum chemotherapy.
- Your cancer is HER2-negative and has tested positive for CLDN18.2 protein.
- You are at least 18 years old, able to take care of yourself (ECOG 0 or 1), and expected to live at least 3 months.
- You have at least one measurable tumor, and any side effects from earlier treatments have mostly resolved.
- You have not had a drug specifically targeting CLDN18.2 (except a certain type of antibody).
- You have no untreated brain metastases, active autoimmune disease, or recent blood clots.
- You can provide a tumor sample (fresh or stored) to confirm CLDN18.2 status.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three treatments—JS107, toripalimab (an immunotherapy), and chemotherapy—for advanced stomach cancer that has a specific protein marker called CLDN18.2. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug called JS207 for people with advanced non-small cell lung cancer (NSCLC) that has gotten worse after standard treatments like chemotherapy and immunotherapy. It aims to see if JS207 can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
This trial tests a new drug called JS212 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can help shrink tumors.
This trial tests a new drug, HS-20093, in people with advanced stomach or gastroesophageal junction cancer that has not responded to other treatments. The goal is to see if it can help shrink or slow the growth of the cancer.
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
Hear when a new Advanced Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.